Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma — Stella

Recruiting

Back to Relapsed Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Massachusetts General Hospital

Collaborators

Sanofi, GlaxoSmithKline

Enrollment target

~50 participants

Started

May 2024

Primary completion

December 2028

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov